All News

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

The COVID-19 pandemic accelerated many changes in the pharmacy field, but maintaining that momentum and working together will be essential for the future growth of pharmacy.

Dolutegravir is a more recently approved ART that is a part of a once-a-day regimen found to be more effective, easier to tolerate, and less likely to create new drug resistance in people with HIV-1 compared with other antiretroviral drugs.

One-third of participants who have used prescriptions think that mail-order pharmacies would help reduce drug costs, according to HealthCare.com.

Sacrosidase was approved by the FDA to treat congenital sucrase-isomaltase deficiency, a condition that inhibits people from breaking down sucrose.

Investigators report that they have seen nearly 100% of the hormone from their tablets going straight into the liver of rats.

A recent study suggests that infrequently taking non-steroidal anti-inflammatory drugs, especially ibuprofen, with type 2 diabetes can increase the risk of first-time heart failure and hospitalization.

A high proportion of myeloid cells may contribute to recurrence in those with long progression-free survival by promoting cancer growth and/or suppressing antitumor immunity.

Processed meats and products high in added sugars and low in fiber contribute to weight gain and obesity, which is an established risk factor.

Findings support the value of expanding this type of health care for patients with opioid use disorder.

The FDA initially approved baloxavir marboxil in October 2018 for the treatment of acute, uncomplicated influenza.

Researchers suggest that understanding the incubation period of COVID-19 and its individual strains could determine the isolation period.

Viloxazine ER treatment was associated with symptom, function, and clinical improvement in adults with attention-deficit hyperactivity disorder.

The mainstay of treatment for schizophrenia and schizoaffective disorder includes antipsychotics.

Doug Long and Scott Biggs of IQVIA discussed how data from Australia can help predict the strength of the upcoming flu season.

Complete recovery of platelet counts after obinutuzumab-based therapy was found to be associated with, or accelerated by, intravenous immunoglobulin.

Patients with chronic migraines and higher frequencies of pain experienced the lowest vitamin B12 levels compared with patients with less frequent or no headache symptoms.

Flublok Quadrivalent and Fluzone High-Dose Quadrivalent are both proven to prevent more cases in older adults compared with a standard-dose vaccine in randomized controlled trials.

Final analysis of phase 2 GRIFFIN study from the Johnson & Johnson subsidiary shows the combination demonstrates stringent complete response rate for transplant-eligible patients.

Pre-specified pooled analysis from phase 3 trials demonstrates 14% reduction in CV mortality and from any cause by 10% in individuals with HF, irrespective of ejection fraction.

A new statement from the American Heart Association stresses withdrawal medications and special care teams to prevent endocarditis in these individuals.

Cognitive harm appears reversible, results of analysis by Nemours Children’s Health Jacksonville and Stanford University shows.

Results from the TOPAZ-1 phase 3 trial showed that the combination reduced risk of death by 20% versus chemotherapy alone.

Analysis shows that over 5 years, the percentage of women without relapse was 89% for those who had hormonal stimulation of the ovaries and 83% for those with ovarian tissue freezing.

Bill Schimmel, CEO and executive director of the Pharmacy Technician Certification Board (PTCB), discusses why pharmacy technicians are leaving the profession and why they are staying.

Students from the Daniel K. Inouye College of Pharmacy discuss their experience at the University of Hawaii.

Predictably, patients in underserved rural, urban communities will face challenges gaining access to approved study sites.

The FDA approved Azurity Pharmaceutical’s omeprazole and sodium bicarbonate for oral suspension to treat benign gastric ulcers and it is predicted to reach commercial markets by next year.